Liquid Biopsy
News and reporting on cell-free DNA testing.
Court Grants Natera Injunction Against Invitae, ArcherDx in Use of Patented Products
The defendants are barred from using Personalized Cancer Monitoring products except for ongoing clinical trials, studies undergoing peer review, and quality control.
The firm hopes that Medicare coverage will facilitate patient access to the NavDx test and spur its inclusion in practice guidelines for head and neck cancer.
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.
Universal DX Closes $70M Series B Round, Inks Deal With Quest to Provide Colorectal Cancer Test
Under the agreement, Quest, an investor in the round, will have exclusive rights to provide Universal's Signal-C colorectal cancer screening test in the US.
ChromaCode Lung Cancer Assay Shows Advantages in New Data at AMP as Company Eyes Next Applications
Premium
The firm is working with early adopters of its NSCLC kit as it develops new tests for cancer minimal residual disease monitoring and kidney transplant rejection.